Expanding ALS Trial Eligibility Could Benefit Patients, Therapeutic Progress

Experts suggest that expanding eligibility for amyotrophic lateral sclerosis (ALS) trials could benefit patients and drug development. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which is an understatement according to investigators. Expanding inclusion criteria would allow more patients to access experimental treatments and help drug develope..